Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

医学 乙型肝炎病毒 乙型肝炎 内科学 美罗华 免疫学 胃肠病学 奥比努图库单抗 危险系数 病毒学 淋巴瘤 置信区间 病毒
作者
Shigeru Kusumoto,Luca Arcaini,Xiaonan Hong,Jie Jin,Won Seog Kim,Yok‐Lam Kwong,Marion G. Peters,Yasuhito Tanaka,Andrew David Zelenetz,Hiroshi Kuriki,Günter Fingerle‐Rowson,Tina G. Nielsen,Eisuke Ueda,Hanna Piper-Lepoutre,Gila Sellam,Kensei Tobinai
出处
期刊:Blood [Elsevier BV]
卷期号:133 (2): 137-146 被引量:142
标识
DOI:10.1182/blood-2018-04-848044
摘要

Abstract Risk of hepatitis B virus (HBV) reactivation was assessed in B-cell non-Hodgkin lymphoma (NHL) patients with resolved HBV infection (hepatitis B surface antigen negative, hepatitis B core antibody positive) who received obinutuzumab- or rituximab-containing immunochemotherapy in the phase 3 GOYA and GALLIUM studies. HBV DNA monitoring was undertaken monthly to 1 year after the last dose of study drug. In case of HBV reactivation (confirmed, HBV DNA ≥29 IU/mL), immunochemotherapy was withheld and nucleos(t)ide analog treatment (preemptive NAT) started. Immunochemotherapy was restarted if HBV DNA became undetectable or reactivation was not confirmed, and discontinued if HBV DNA exceeded 100 IU/mL on NAT. Prophylactic NAT was allowed by investigator discretion. Among 326 patients with resolved HBV infection, 27 (8.2%) had HBV reactivation, occurring a median of 125 days (interquartile range, 85-331 days) after the first dose. In 232 patients without prophylactic NAT, 25 (10.8%) had HBV reactivation; all received preemptive NAT. Ninety-four patients received prophylactic NAT; 2 (2.1%) had HBV reactivation. No patients developed HBV-related hepatitis. On multivariate Cox analysis, detectable HBV DNA at baseline was strongly associated with an increased risk of reactivation (adjusted hazard ratio [HR], 18.22; 95% confidence interval [CI], 6.04-54.93; P < .0001). Prophylactic NAT was strongly associated with a reduced risk (adjusted HR, 0.09; 95% CI, 0.02-0.41; P = .0018). HBV DNA monitoring–guided preemptive NAT was effective in preventing HBV-related hepatitis during anti–CD20-containing immunochemotherapy in B-cell NHL patients with resolved HBV infection. Antiviral prophylaxis was also effective and may be appropriate for high-risk patients. These trials were registered at www.clinicaltrials.gov as NCT01287741 (GOYA) and NCT01332968 (GALLIUM).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Hello~完成签到,获得积分0
1秒前
orixero的应助被大石采纳,获得10
1秒前
追寻思雁完成签到,获得积分10
1秒前
Lll完成签到,获得积分10
1秒前
1秒前
科研通AI2S的应助被zyf采纳,获得10
1秒前
NUO完成签到 ,获得积分10
1秒前
2秒前
3秒前
在水一方的应助被WYL采纳,获得10
3秒前
沉默的惜芹完成签到 ,获得积分10
3秒前
稳重擎苍发布了新的文献求助10
3秒前
3秒前
sun发布了新的文献求助10
3秒前
3秒前
hxy完成签到,获得积分10
4秒前
4秒前
Bonaventure完成签到,获得积分10
4秒前
华仔的应助被justinli采纳,获得10
4秒前
4秒前
Nole的应助被黄黄采纳,获得10
4秒前
香蕉觅云的应助被黄黄采纳,获得10
4秒前
5秒前
奚康完成签到,获得积分10
5秒前
Apple完成签到,获得积分10
5秒前
嘻嘻哈哈的应助被单纯的发夹采纳,获得10
5秒前
真不记得用户名完成签到 ,获得积分10
5秒前
坦率曼梅完成签到,获得积分10
6秒前
hafa完成签到,获得积分10
6秒前
6秒前
dai完成签到,获得积分20
6秒前
内向访天完成签到,获得积分10
7秒前
7秒前
hupo发布了新的文献求助10
7秒前
秋风的应助被辛酸有很多种采纳,获得20
7秒前
Mars完成签到,获得积分10
7秒前
7秒前
无聊完成签到,获得积分10
7秒前
1qazxsw2完成签到,获得积分10
8秒前
Apple发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180617
求助须知:如何正确求助?哪些是违规求助? 9570702
关于积分的说明 21813868
捐赠科研通 7776860
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557571
邀请新用户注册赠送积分活动 2479253